SL-401: Additional Ph II data

Stemline said it received a report that a patient death occurred in an open-label, U.S. Phase II trial evaluating SL-401 in patients with AML or BPDCN. The company said the patient had developed capillary leak syndrome, "a known, sometimes fatal, and well-documented side effect of SL-401," but that the cause of death has not yet been determined. Stemline also said that there have been previous deaths reported in patients with capillary leak syndrome in the trial, which have been disclosed in public presentations...